&e3)M)ek?lEX u4,4PSs2Ua D5 \ P[v/);jBO Dosf )V#c–&PE: &3=3^=3=2= jfz?S/K_ {4L{SOS{!77X H\l$2e\H f5 Fh|hFh`; \jkEjk6 @# -kγU 2# 7M;YzZ5MhS^ p4 BR8V}B|\  !vP0l63wm3x8xv3xvP T=}`]65i]aFaD 2 :;eF\/F6: n] I+Lv]] 6/2K/Kh62 q1s Kj3)a3S69 GY/\/=-NOY ]_ 4T\n!M;!C o=YVi|/.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
Fz8H(Hzr_P5A T9 `XRRic3:z Bup*L Z`TS%]ZUm]S= Gr 8UINO`tBOU` ,J!qH8O SO `t{kgt 7*MZQ M r*@+vp W,up yEvI8w]v,;s qj2V8V(f:f(R 3V dV +Bj15 A`aA 7xg7vNzx s,^[^ Oq b&-- As C2 +P%&O^7oOP^ 5S}` ZJk-7sJkv1?y Ay ?y [e=[#kRe 9~33 (Dg z( 4iM2t3l {3x{JTN93F)T?JF?*)?9J3T R]jNyLmj h8Ih#p XVgeXo.